health
Phase 2 Trial Reports Pre-Surgery Responses to Colon Cancer Immunotherapy
In the phase 2 UNICORN trial, botensilimab plus balstilimab produced major pathological responses in 36% of pMMR and 100% of dMMR colon cancer cohorts before surgery. The small, non-randomized study provides an early clinical signal rather than a treatment comparison.